Skip to main content

Ocrevus Side Effects

Generic name: ocrelizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Dec 27, 2022.

Note: This document contains side effect information about ocrelizumab. Some dosage forms listed on this page may not apply to the brand name Ocrevus.

Summary

Common side effects of Ocrevus include: lower respiratory tract infection, upper respiratory tract infection, cough, and infusion related reaction. Continue reading for a comprehensive list of adverse effects.

Applies to ocrelizumab: parenteral concentrate for iv infusion.

Side effects include:

Relapsing forms of MS (≥10%): upper respiratory tract infection and infusion reaction.

PPMS (≥10%): upper respiratory tract infection, infusion reaction, skin infection, and lower respiratory tract infection.

For Healthcare Professionals

Applies to ocrelizumab: intravenous solution.

Respiratory

Very common (10% or more): Upper respiratory tract infection (49%), nasopharyngitis (24%), lower respiratory tract infection (10%)

Common (1% to 10%): Bronchitis, cough[Ref]

Psychiatric

Common (1% to 10%): Depression[Ref]

Oncologic

Uncommon (0.1% to 1%): Breast cancer[Ref]

Musculoskeletal

Common (1% to 10%): Back pain, pain in extremity[Ref]

Local

Very common (10% or more): Infusion reactions (40%)[Ref]

Immunologic

Common (1% to 10%): Herpes virus associated infections

Frequency not reported: Immunogenicity[Ref]

Hematologic

Very common (10% or more): Neutrophil levels decreased (13%)[Ref]

Dermatologic

Very common (10% or more): Skin infections (14%)[Ref]

Ocular

Common (1% to 10%): Conjunctivitis[Ref]

Metabolic

Common (1% to 10%): Peripheral edema[Ref]

Frequently asked questions

References

1. Product Information. Ocrevus (ocrelizumab). Genentech. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.